MAYNE PHARMA GROUP LIMITED — Director's Dealing 2016

Aug 15, 2016

Appendix 3Y Change of Director’s Interest Notice

Rule 3.19A.2

Appendix 3Y

Change of Director’s Interest Notice

Information or documents not available now must be given to ASX as soon as available. Information and documents given to ASX become ASX’s property and may be made public.

Introduced 30/09/01 Amended 01/01/11

Name of entity Mayne Pharma Group Limited ABN 76 115 832 963

We (the entity) give ASX the following information under listing rule 3.19A.2 and as agent for the director for the purposes of section 205G of the Corporations Act.

Name of Director	Ron Best
Date of last notice	7 July 2016

Part 1 - Change of director’s relevant interests in securities

In the case of a trust, this includes interests in the trust made available by the responsible entity of the trust

Note: In the case of a company, interests which come within paragraph (i) of the definition of “notifiable interest of a director” should be disclosed in this part.

Direct or indirect interest	Indirect interest
Nature of indirect interest (including registered holder) Note: Provide details of the circumstances giving rise to the relevant interest.	Bremal Pty Ltd (1) Louise Asher (2)
Date of change	16 Aug 2016 (1) 22 Jul 2016(2)
No. of securities held prior to change	1,488,289 Ordinary shares (1) 42,338 Ordinary shares (2)
Class	Ordinary shares
Number acquired	52,336 Ordinary shares (1) 24,543 Ordinary (2)
Number disposed	39,000 shares (1)
Value/Consideration Note: If consideration is non-cash, provide details and estimated valuation	$66,990.08 purchase (1) $49,920.00 disposal (1) $31,415.04 purchase (2)
No. of securities held after change	1,501,625 Ordinary shares (1) 66,881 Ordinary shares (2)

• See chapter 19 for defined terms.

01/01/2011 Appendix 3Y Page 1

Appendix 3Y Change of Director’s Interest Notice

Nature of change Purchase: Shares issued as part of the retail entitlement offer Example: on-market trade, off-market trade, that was announced on 28 June 2016 exercise of options, issue of securities under Sale: Off-market transfer dividend reinvestment plan, participation in buyback

Part 2 – Change of director’s interests in contracts

Note: In the case of a company, interests which come within paragraph (ii) of the definition of “notifiable interest of a director” should be disclosed in this part.

Detail of contract Nature of interest Name of registered holder (if issued securities) Date of change No. and class of securities to which interest related prior to change Note: Details are only required for a contract in relation to which the interest has changed Interest acquired Interest disposed Value/Consideration Note: If consideration is non-cash, provide details and an estimated valuation Interest after change

Part 3 –[+] Closed period

Were the interests in the securities or contracts detailed No above traded during a[+] closed period where prior written clearance was required? If so, was prior written clearance provided to allow the trade N/A to proceed during this period? If prior written clearance was provided, on what date was this N/A provided?

• See chapter 19 for defined terms.

Appendix 3Y Page 2

01/01/2011